Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for CDNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 9.481M
March 31, 2026 -1.10M
December 31, 2025 10.79M
September 30, 2025 25.33M
June 30, 2025 47.57M
March 31, 2025 -3.922M
December 31, 2024 -5.614M
September 30, 2024 -4.056M
June 30, 2024 -0.123M
March 31, 2024 -0.018M
December 31, 2023 25.96M
September 30, 2023 -0.325M
June 30, 2023 0.058M
March 31, 2023 0.232M
December 31, 2022 0.357M
September 30, 2022 -1.37M
June 30, 2022 -0.413M
March 31, 2022 -2.597M
December 31, 2021 -1.855M
September 30, 2021 -3.295M
June 30, 2021 -7.048M
March 31, 2021 -191.58M
December 31, 2020 -4.537M
September 30, 2020 -1.736M
June 30, 2020 -160.77M
Date Value
March 31, 2020 -0.817M
December 31, 2019 -0.308M
September 30, 2019 -0.895M
June 30, 2019 -1.431M
March 31, 2019 -1.784M
December 31, 2018 -54.76M
September 30, 2018 -10.33M
June 30, 2018 -0.456M
March 31, 2018 -0.137M
December 31, 2017 -19.58M
September 30, 2017 -0.049M
June 30, 2017 0.00
March 31, 2017 -0.044M
December 31, 2016 0.36M
September 30, 2016 -8.428M
June 30, 2016 -20.62M
March 31, 2016 -0.181M
December 31, 2015 -0.204M
September 30, 2015 -0.003M
June 30, 2015 -0.031M
March 31, 2015 -0.011M
December 31, 2014 -3.73M
September 30, 2014 -36.44M
June 30, 2014 0.908M
March 31, 2014 -0.004M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Natera, Inc. -17.30M
Caris Life Sciences, Inc. 17.68M
Myriad Genetics, Inc. -2.80M
BioRestorative Therapies, Inc. -4.441M
Exagen, Inc. 0.00